Flying into London recently for the Jefferies Conference, Novavax’s EVP, chief commercial officer, and chief business officer John Trizzino, together with the comp
Pfizer and BioNTech have announced that they have submitted an Emergency Use Authorisation (EUA) to the US Food and Drug Administration (FDA) for their Omicron BA.4/BA.5-adapted bivalent CO
Karl Goossens, director of commercial analytics at Veeva Systems Europe, recently spoke with pharmaphorum, discussing how effective omnichannel execution drives revenue and productivity.
NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer's Paxlovid, Roche's RoActemra, and Eli Lilly's Olumiant – but turned down another five
For all their long history in vaccines, GSK and Sanofi have struggled to get a shot for COVID-19 authorised – but they have finally crossed the finish line in Europe.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.